HONG KONG – The anti-diabetic drug, metformin, is a promising candidate for an effective adjunctive host therapy for boosting the efficacy of current tuberculosis (TB) treatments, Singapore Immunology Network (SIgN) researchers with the Agency for Science, Technology and Research (A*STAR) reported in the Nov. 19, 2014, edition of Science Translational Medicine.